Company intelligence / Profile preview
TC BioPharm
- Ownership
- Public · TCBP
- Employees
- ~100
- Development stage
- Phase 2
Overview
TC BioPharm has demonstrated human efficacy data in acute myeloid leukemia and leads the field as the first company to conduct phase II/pivotal clinical studies with gamma-delta T cells in oncology. The company’s lead program uses its proprietary CryoTC technology to deliver frozen allogeneic products globally. Two investigator-led trials are ongoing for unmodified gamma-delta T cell products.
- Therapeutic areas
- OncologyInfectious DiseasesHematology
- Modalities
- Allogeneic CAR-T cell therapyGamma delta T cell therapy
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Partnerships
Financials
- Market cap
- $256.5K
- Total revenue
- $0
- Enterprise value
- $905.7K
Beyond the preview
Go deeper on TC BioPharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TC BioPharm.